Larazotide Solubility & Diluents — Research Reference

Larazotide, an investigational tight-junction-regulating peptide, presents specific solubility and stability considerations that are paramount for its effective utilization in diverse research applications. Optimal dissolution protocols and judicious selection of diluents are fundamental to ensuring the peptide’s structural integrity, functional activity, and experimental reproducibility across numerous PubMed publications and several registered ClinicalTrials.gov studies exploring its potential in intestinal barrier research.

This comprehensive reference delves into the physicochemical properties that govern Larazotide’s behavior in solution, providing researchers with foundational knowledge and practical strategies for its preparation, handling, and storage. From the intrinsic factors influencing peptide solubility to the selection of appropriate aqueous buffers, organic co-solvents, and stabilizing excipients, this resource aims to equip investigators with the insights necessary to overcome common challenges and advance their studies with confidence and precision, exclusively within a research-use-only context.

Understanding Larazotide: Peptide Structure and Research Context

Larazotide, also known by its alias AT-1001, represents a significant focus in intestinal barrier research as a tight-junction-regulating peptide. Its classification as a tight-junction peptide immediately signals its intended biological role: modulating the paracellular pathway, which controls the permeability of epithelial and endothelial cell layers. Tight junctions are multi-protein complexes that seal the space between adjacent cells, forming a selective barrier that regulates the passage of ions, solutes, and water. Dysregulation of these junctions is implicated in various pathological conditions, particularly those involving gastrointestinal inflammation and compromised barrier function. Understanding the precise molecular interactions of Larazotide with these complex structures is crucial for elucidating its full spectrum of effects and optimizing its application in research settings.

The peptide’s mechanism of action primarily involves interactions with specific components of the tight junction machinery. While detailed structural information, such as its full amino acid sequence, is often proprietary or not fully disclosed in public domains for commercial reasons, its classification as a “peptide” suggests it is composed of a relatively short chain of amino acids linked by peptide bonds. The specific sequence and conformation of Larazotide are paramount to its ability to selectively modulate tight junction function without broad, non-specific cellular effects. Researchers are keenly interested in how its unique primary and secondary structures enable it to exert its regulatory influence, making it a valuable tool for probing intestinal permeability and barrier integrity in diverse experimental models. For a deeper dive into the specific molecular interactions, researchers can consult resources discussing Larazotide’s mechanism of action.

The research landscape surrounding Larazotide is extensive and continually expanding, underscoring its relevance and potential utility in biological investigations. Indexed in numerous PubMed publications, studies involving Larazotide span a wide array of topics, from basic epithelial cell biology to complex animal models of intestinal dysfunction. These publications frequently explore its effects on gut permeability in conditions such as inflammatory bowel disease (IBD), celiac disease, and various forms of enteropathy, providing a robust body of evidence for its modulating capabilities. Furthermore, several registered studies on ClinicalTrials.gov highlight its progression into human investigational stages, signifying the scientific community’s sustained interest in its potential for translational research. These clinical trial registrations, while not indicative of approval or safety for human use, reflect a comprehensive research trajectory aimed at understanding its biological impact in carefully controlled human subject protocols.

For researchers, the existence of both extensive preclinical data and human research registrations offers a rich foundation for experimental design. This breadth of documented investigation provides critical context for interpreting solubility profiles, optimizing diluents, and ensuring the stability of Larazotide solutions. The consistent reporting of its role in intestinal-barrier research across multiple scientific platforms reinforces its established identity as a valuable probe for studying barrier function. Consequently, researchers preparing Larazotide for experimental use must consider these established research contexts to guide their handling and formulation decisions, striving to replicate or improve upon documented methodologies to ensure experimental rigor and reproducibility.

Fundamentals of Peptide Solubility: General Biochemical Principles

Peptide solubility is a multifaceted biochemical property governed by an intricate interplay of intrinsic peptide characteristics and extrinsic environmental factors. At its core, solubility refers to the maximum amount of a substance (the solute, in this case, the peptide) that can dissolve in a given amount of solvent at a specific temperature, forming a homogeneous solution. For peptides, this property is not merely a practical concern for solution preparation but is often deeply intertwined with their biological activity and structural integrity. A peptide’s ability to remain in solution directly impacts its bioavailability in experimental systems, its ability to interact with target molecules, and the consistency of research outcomes. Poor solubility can lead to aggregation, precipitation, and reduced biological efficacy, necessitating a comprehensive understanding of the underlying principles.

The primary determinants of peptide solubility stem from its amino acid composition and sequence. Each amino acid possesses a unique side chain (R-group) that can be broadly classified as hydrophobic, hydrophilic (polar uncharged), acidic (negatively charged), or basic (positively charged). Hydrophobic amino acids, such as leucine, isoleucine, valine, and phenylalanine, tend to reduce solubility in aqueous solvents, promoting aggregation through hydrophobic interactions. Conversely, hydrophilic amino acids, like serine, threonine, glutamine, and asparagine, as well as charged amino acids (lysine, arginine, histidine, aspartic acid, glutamic acid), enhance solubility through hydrogen bonding and electrostatic interactions with water molecules. The relative proportion and strategic placement of these residues along the peptide chain significantly dictate its overall hydrophilicity or hydrophobicity. Furthermore, the peptide’s length also plays a role; generally, longer peptides with more extensive hydrophobic regions tend to be less soluble than shorter ones, though specific sequence motifs can override this generalization.

Beyond composition, the pH of the solvent is arguably one of the most critical extrinsic factors influencing peptide solubility. Peptides are polyampholytes, meaning they possess multiple ionizable groups (N-terminus, C-terminus, and ionizable side chains). The net charge of a peptide is highly dependent on the solution’s pH relative to the pKa values of these groups. At the isoelectric point (pI), the pH at which the peptide carries no net electrical charge, its solubility is typically at its minimum. This is because electrostatic repulsion between molecules is minimized, allowing hydrophobic interactions to dominate and promote aggregation or precipitation. Conversely, moving the pH away from the pI, either towards more acidic or more basic conditions, increases the net charge of the peptide, enhancing its interaction with polar water molecules and consequently increasing solubility.

Other significant factors include ionic strength, temperature, and the presence of co-solvents or excipients. High salt concentrations (ionic strength) can have a dual effect: low concentrations can enhance solubility by screening electrostatic charges and preventing aggregation (salting in), while excessively high concentrations can “salt out” peptides by competing for water molecules and reducing their hydration shell. Temperature generally increases solubility by enhancing molecular motion and disrupting intermolecular forces, though excessive heat can lead to denaturation and aggregation for some peptides. The addition of co-solvents, such as organic solvents (e.g., acetonitrile, DMSO, DMF) or detergents, can alter the solvent’s dielectric constant and hydrogen bonding network, thereby enhancing solubility for challenging peptides.

Key Factors Influencing Peptide Solubility:

• Amino Acid Composition: Ratio of hydrophobic to hydrophilic/charged residues.
• Peptide Length: Generally, shorter peptides are more soluble, but sequence matters more.
• Primary Sequence: Specific order of amino acids, determining charge distribution and potential for secondary structures.
• Net Charge and Isoelectric Point (pI): pH-dependent ionization of N-terminus, C-terminus, and side chains. Solubility is lowest near pI.
• Hydrophobicity/Hydrophilicity: Overall balance of polar and nonpolar characteristics.
• Secondary and Tertiary Structure: Folding patterns can bury hydrophobic residues or expose hydrophilic ones, affecting surface interactions.
• Solvent pH: Crucial for determining the peptide’s net charge.
• Ionic Strength: Concentration of salts; can cause salting in or salting out.
• Temperature: Generally increases solubility, but can cause denaturation at extremes.
• Presence of Co-solvents: Organic solvents, chaotropes, or detergents can enhance solubility.

Physicochemical Properties of Larazotide: Implications for Solubility

To effectively work with Larazotide in research, it is imperative to consider its specific physicochemical properties, which directly dictate its solubility behavior. While the exact amino acid sequence and precise three-dimensional structure of Larazotide (AT-1001) are typically proprietary, its classification as a “tight-junction-regulating peptide” provides crucial clues regarding its likely characteristics. Peptides that interact with biological membranes or protein complexes like tight junctions often possess a delicate balance of hydrophilic and hydrophobic residues to enable both aqueous solubility and specific binding. An excessively hydrophobic peptide would be prone to aggregation and precipitation in physiological buffers, while an overly hydrophilic one might lack the necessary interactions for specific binding to membrane-associated or junctional proteins. Therefore, Larazotide is likely engineered or naturally evolved to strike this balance.

Given its regulatory role at cellular junctions, Larazotide is presumed to have a defined secondary and potentially tertiary structure crucial for its biological activity. Such structures often involve specific folding patterns that expose certain residues to the solvent while burying others. The overall surface charge distribution and the presence of accessible charged or polar residues will significantly influence its interaction with water molecules and, consequently, its aqueous solubility. A peptide’s isoelectric point (pI) is a critical parameter derived from its amino acid composition. If Larazotide has a pI close to neutral pH (e.g., pH 7.0-7.4), its solubility in standard physiological buffers like PBS might be suboptimal due to minimal net charge, increasing its propensity to aggregate. Conversely, a pI significantly deviating from neutrality would suggest higher solubility at physiological pH due to a substantial net charge. Researchers should consider empirically determining the optimal pH range for Larazotide dissolution by testing various pH buffers.

The molecular weight of Larazotide, as a peptide, would typically fall within a range that suggests it is not overly large, which usually aids solubility. However, the presence of specific hydrophobic domains or sequences prone to self-association, even in a moderately sized peptide, can present solubility challenges. Such domains might drive intermolecular interactions leading to fibril formation or amorphous aggregation, especially at higher concentrations. Furthermore, post-translational modifications, if present, could also significantly alter its solubility profile. For instance, glycosylation can increase hydrophilicity, while lipidation or disulfide bond formation can alter conformation and exposure of hydrophilic/hydrophobic patches. While no specific post-translational modifications are publicly specified for Larazotide, it is a general consideration for any peptide.

In practical terms for research, these physicochemical insights guide the initial selection of diluents and dissolution strategies. For Larazotide, as with many bioactive peptides, it is often prudent to start with weakly acidic solutions (e.g., 0.1% acetic acid) or basic solutions (e.g., ammonium hydroxide) to ensure initial complete dissolution, especially if its pI is near neutrality. This initial dissolution step can help overcome strong intermolecular forces, after which the solution can be diluted into a physiological buffer at the desired experimental pH. Awareness of its primary research context in intestinal-barrier studies also suggests that its final solution must be compatible with biological systems, implying the need for sterile, isotonic, and pH-appropriate buffers for experimental application. Diluents containing strong organic solvents should be used with caution and minimal concentrations if the final application requires biological compatibility, as these can denature the peptide or interfere with cellular processes.

Primary Research Diluents for Larazotide Preparation

The selection of an appropriate diluent is perhaps the most critical initial step in preparing Larazotide solutions for research applications. The chosen solvent not only dictates the peptide’s initial dissolution but also profoundly influences its long-term stability and biological activity in experimental systems. A universal solvent for all peptides does not exist, and the optimal diluent for Larazotide will depend heavily on its specific physicochemical properties, the desired concentration, and the ultimate application. Researchers must approach this decision systematically, often requiring preliminary empirical tests to confirm complete dissolution and stability.

For many peptides, including those that are moderately hydrophobic or contain multiple charged residues, ultra-pure water is often the first diluent considered. However, Larazotide, as a tight-junction peptide, may have specific structural features that necessitate alternative starting solvents. If Larazotide’s pI is close to 7.0, plain deionized water might not be sufficient to achieve complete dissolution, especially at higher concentrations, due to minimal net charge. In such cases, adjusting the pH of the initial solvent is often necessary. Weakly acidic solutions, such as 0.1% (v/v) acetic acid, are commonly employed to protonate basic residues (lysine, arginine, histidine) and the N-terminus, increasing the peptide’s net positive charge and improving solubility. Conversely, for peptides with an acidic pI, a weakly basic solution, such as a dilute ammonium hydroxide (NH₄OH) solution, can deprotonate acidic residues (aspartic acid, glutamic acid) and the C-terminus, yielding a net negative charge and enhancing solubility.

Once Larazotide is fully dissolved in an initial pH-adjusted solvent, it can then be diluted into the desired experimental buffer, such as Phosphate-Buffered Saline (PBS), HEPES buffer, or cell culture media, ensuring that the final concentration of the initial solvent is sufficiently low (e.g., <1% acetic acid) to avoid altering the experimental conditions. PBS is a common choice for biological assays due to its physiological pH and isotonicity, but its buffering capacity must be respected; adding a highly acidic or basic Larazotide stock solution to a small volume of PBS can overwhelm its buffering capacity and change the final pH. Therefore, large dilutions or slow, incremental additions with constant pH monitoring are recommended.

For particularly challenging peptides with significant hydrophobicity, or when very high stock concentrations are required, a small percentage of organic co-solvents may be necessary. Dimethyl sulfoxide (DMSO) and Dimethylformamide (DMF) are two such options, typically used at concentrations between 1% and 10% (v/v) in water or buffer. While highly effective at dissolving hydrophobic peptides by disrupting intermolecular interactions, both DMSO and DMF can be cytotoxic at higher concentrations and may affect biological activity. Therefore, their use should be minimized, and controls should be run to assess any solvent-related effects in the experimental system. Ethanol and acetonitrile are other options, but their volatility and potential for peptide precipitation upon dilution must be considered.

Common Diluents and Their Applications for Peptide Dissolution:

• Ultrapure Water: Suitable for highly hydrophilic or charged peptides. Often a starting point, but may require pH adjustment for many peptides.
• 0.1% Acetic Acid (v/v): Excellent for basic peptides or peptides with a pI near neutrality. Increases positive charge. Provides a good initial stock solution that can be diluted into neutral buffers.
• Dilute Ammonium Hydroxide (e.g., 0.1M NH₄OH): Useful for acidic peptides or peptides with a pI near neutrality. Increases negative charge. Similarly, provides a good initial stock.
• Phosphate-Buffered Saline (PBS): Physiological buffer, ideal for biological applications once the peptide is dissolved. Ensure pH compatibility with the peptide’s net charge profile.
• Dimethyl Sulfoxide (DMSO) / Dimethylformamide (DMF): Potent solvents for hydrophobic peptides. Use at minimal concentrations (e.g., <5%) in aqueous solutions to mitigate cytotoxicity.
• Acetonitrile (ACN) / Ethanol: Can be used for very hydrophobic peptides, often in combination with water. Careful consideration of final concentration and precipitation risk is needed.

Optimization Strategies for Larazotide Dissolution

Achieving complete and stable dissolution of Larazotide is paramount for accurate and reproducible research. When initial attempts with standard diluents prove insufficient, researchers must employ systematic optimization strategies. These strategies aim to overcome the intermolecular forces that prevent peptides from dissolving, ensuring that the peptide is fully available in its intended soluble form for experimental use. The goal is to maximize solubility while preserving the peptide’s structural integrity and biological activity.

One of the most effective strategies involves pH adjustment, particularly if Larazotide’s pI is close to the pH of the intended physiological buffer. By initially dissolving Larazotide in a solvent with a pH significantly different from its pI (either strongly acidic or basic, depending on its calculated or estimated pI), the peptide gains a net charge, enhancing its interaction with polar water molecules and reducing self-aggregation. For example, if Larazotide is challenging to dissolve in neutral buffer, an initial dissolution in 0.1% acetic acid (pH ~2.5) or a dilute basic solution (e.g., 50 mM ammonium bicarbonate, pH ~8.0-9.0) might be effective. Once fully dissolved, this concentrated stock can then be gradually diluted into the desired neutral physiological buffer, monitoring the pH to prevent localized precipitation upon dilution. It is crucial to use dilute acids or bases, as extreme pH can lead to peptide degradation or denaturation.

Temperature and mechanical agitation are also key physical methods for optimizing dissolution. Gentle warming (e.g., to 30-37°C) can increase the kinetic energy of the system, disrupting intermolecular hydrogen bonds and hydrophobic interactions that hinder dissolution. However, excessive heat should be avoided, as it can induce denaturation, aggregation, or chemical degradation of the peptide. Sonication, particularly using a bath sonicator (rather than a probe sonicator which can cause localized heating and cavitation damage), can help disperse peptide aggregates and facilitate interaction with the solvent. Vortexing or gentle shaking can also promote dissolution by ensuring fresh solvent molecules come into contact with the solid peptide. These methods should always be applied cautiously and briefly to avoid damage to the peptide.

For highly hydrophobic Larazotide preparations, or when very high concentrations are required, the judicious use of co-solvents can be indispensable. Co-solvents such as DMSO, DMF, or even low concentrations of denaturants like urea or guanidine hydrochloride, can alter the solvent’s polarity and hydrogen bonding network, making it more favorable for peptide dissolution. However, the concentration of co-solvents must be carefully controlled, especially if the solution is intended for cell-based assays or in vivo studies, due to potential cytotoxicity or interference with biological processes. Typically, concentrations of organic co-solvents should be kept below 1-5% (v/v) in the final assay medium. The purity of the peptide itself is also a critical factor; impurities can interfere with dissolution. Researchers should always refer to the quality testing documentation, such as a Certificate of Analysis, to confirm peptide purity before troubleshooting solubility issues.

Finally, a sequential dissolution approach can often resolve persistent solubility issues. This involves adding a minimal volume of a strong, primary solvent (e.g., 0.1% acetic acid or a small percentage of DMSO) to fully dissolve the peptide, followed by gradual dilution with the intended aqueous buffer. This method ensures that the peptide is completely solubilized before being introduced to an environment where it might be less soluble. For instance, dissolving Larazotide in 100 µL of 0.1% acetic acid, then gradually adding 900 µL of PBS to achieve a 1 mL final volume, is often more effective than directly attempting to dissolve it in 1 mL of PBS. This stepwise approach mitigates the risk of localized supersaturation and subsequent precipitation.

Factors Influencing Larazotide Solution Stability and Longevity

Maintaining the stability and longevity of Larazotide solutions is just as critical as achieving initial dissolution, particularly for long-term research projects or when preparing stock solutions for multiple experiments. Peptide degradation in solution can lead to loss of biological activity, altered physicochemical properties, and irreproducible experimental results. Several intrinsic and extrinsic factors govern the stability of Larazotide in solution, and understanding these is key to implementing effective storage strategies.

One of the most significant factors is temperature. Elevated temperatures accelerate chemical reactions, including peptide degradation pathways such as hydrolysis, oxidation, and deamidation. Therefore, Larazotide solutions should generally be stored at low temperatures, typically -20°C or -80°C, to minimize degradation rates. While freezing is effective, repeated freeze-thaw cycles should be avoided, as they can induce aggregation, particularly in peptides prone to self-association, and can also lead to the formation of ice crystals that mechanically stress peptide molecules. Aliquoting stock solutions into smaller, single-use volumes before freezing is a recommended practice to mitigate this.

The pH of the solution plays a crucial role not only in solubility but also in stability. Peptides are generally most stable within a specific pH range, often near neutral pH, but this can vary depending on the amino acid composition. Extremes of pH (highly acidic or highly basic) can promote hydrolysis of peptide bonds, particularly at elevated temperatures. For Larazotide, identifying its optimal stability pH range—which may differ from its optimal solubility pH—is important. Buffers with good buffering capacity in the desired pH range should be used to maintain a stable pH over time, preventing fluctuations that could lead to degradation or precipitation. Common biological buffers like PBS, HEPES, or Tris can be effective choices, provided they are used within their optimal buffering range.

Chemical degradation pathways, such as oxidation and deamidation, can significantly impact peptide stability. Oxidation primarily affects methionine, tryptophan, cysteine, and tyrosine residues and is often catalyzed by light or the presence of trace metal ions. To minimize oxidation, Larazotide solutions should be stored in amber vials or wrapped in foil to protect them from light, and in an oxygen-free environment (e.

Frequently Asked Questions

What is the primary class and mechanism of action for Larazotide in research?

Larazotide is classified as a tight-junction-regulating peptide, and its mechanism of action involves modulating the integrity of intestinal epithelial tight junctions, a focus of extensive research in barrier function studies.

Why is understanding Larazotide’s solubility crucial for research?

Accurate solubility data and proper dissolution techniques are essential for preparing stable, homogenous solutions, ensuring consistent dosing in *in vitro* assays or *in vivo* animal models, and maintaining the peptide’s biochemical activity and structural integrity throughout experimental procedures.

What are the general categories of diluents used for peptide research?

Common diluents include aqueous buffers (e.g., PBS, HEPES, TRIS) for physiological pH ranges, organic co-solvents (e.g., DMSO, DMF, acetonitrile) for peptides with high hydrophobicity, and occasionally dilute acidic or basic solutions to optimize charge state.

Can organic solvents like DMSO be used for Larazotide in cell-based assays or animal models?

While organic co-solvents such as DMSO can aid initial dissolution of hydrophobic peptides, their use in cell-based assays or *in vivo* animal models requires careful consideration of potential cytotoxicity or physiological effects, typically necessitating extremely low final concentrations or alternative aqueous diluents for subsequent dilutions.

What factors might lead to Larazotide precipitation in solution?

Precipitation can result from exceeding the peptide’s solubility limit, incorrect pH, high ionic strength, temperature extremes, prolonged storage, or the presence of impurities. Aggregation due to hydrophobic interactions is also a common cause.

How can researchers verify the solubility and stability of prepared Larazotide solutions?

Solubility and stability can be assessed using various analytical techniques such as UV-Vis spectrophotometry to monitor concentration, HPLC for purity and degradation products, and dynamic light scattering (DLS) to detect aggregation or particle formation.

What are the recommended general guidelines for storing Larazotide stock solutions?

Larazotide stock solutions are typically recommended for storage at -20°C or -80°C in aliquots to minimize freeze-thaw cycles, protected from light and atmospheric oxygen, and within appropriately buffered solutions to maintain stability.

Are there any specific additives that can improve Larazotide solubility or stability in research?

Depending on the specific research application, certain additives like low concentrations of non-ionic detergents (e.g., Tween, Pluronic), cyclodextrins, or stabilizing sugars (e.g., trehalose) might be explored to enhance solubility or reduce aggregation and degradation.

Scientific References

• PubMed: Larazotide
• ClinicalTrials.gov: Larazotide

All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.